GYRE THERAPEUTICS, INC. GYRE
In this section, unless otherwise specified, references to "we," "our," "us" and "our company" refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) ("Gyre Pharmaceuticals").
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.
In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY® (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M | — | $6.0K | $1.0M | — |
| Cost of revenue | $5.4M | $3.9M | $4.6M | $4.8M | — | — | — | — | — | — |
| Gross profit | $111.2M | $101.9M | $108.8M | $97.5M | — | — | — | — | — | — |
| R&D | $13.7M | $12.0M | $13.8M | — | $68.9M | $53.0M | $43.9M | $21.5M | $12.8M | $11.6M |
| SG&A | $20.8M | $16.1M | $14.7M | $17.4M | $19.0M | $16.2M | $13.4M | $12.4M | $10.0M | $9.3M |
| Total operating expenses | $105.1M | $89.6M | $176.0M | $88.3M | $95.2M | $78.3M | $57.3M | $33.8M | $22.8M | $20.8M |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M | -$57.4M | -$57.3M | -$33.8M | -$21.8M | -$20.4M |
| Interest expense | $1.7M | $1.5M | $1.0M | $726.0K | — | — | — | — | — | — |
| Pre-tax income | $14.4M | $23.2M | -$77.0M | $9.4M | -$87.9M | — | — | — | — | — |
| Income tax | $4.6M | $5.3M | $8.5M | $5.1M | — | — | — | — | — | — |
| Net income | $9.9M | $17.9M | -$85.5M | $4.3M | -$87.9M | -$56.2M | -$55.2M | -$30.1M | -$21.6M | -$16.9M |
| EPS, basic | 0.06 | 0.14 | -1.41 | 0.04 | -2.87 | — | — | — | — | — |
| EPS, diluted | 0.02 | 0.05 | -1.41 | 0.03 | -2.87 | -2.93 | -4.60 | -2.68 | -7.45 | -21.75 |
| Shares, diluted (wtd. avg.) | 103.2M | 102.3M | 65.8M | 75.7M | 30.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $37.1M | $11.8M | $33.5M | $25.2M | $44.3M | $30.4M | $15.4M | $31.2M | $14.5M | $10.3M |
| Short-term investments | $15.4M | $14.9M | — | $0 | $2.5M | $49.0M | $61.5M | $88.9M | $18.0M | $6.8M |
| Receivables | $31.1M | $19.6M | $15.2M | — | $1.8M | $3.3M | $15.0M | — | — | — |
| Inventory | — | $6.3M | $4.3M | $6.1M | — | — | — | — | — | — |
| Total current assets | $102.4M | $64.8M | $57.2M | $49.7M | $51.5M | $89.5M | $96.1M | $124.0M | $39.1M | $37.5M |
| Property, plant and equipment | $23.6M | $23.9M | $23.3M | $17.7M | $970.0K | $433.0K | $304.0K | $386.0K | $276.0K | $444.0K |
| Other intangibles | $4.7M | $273.0K | $205.0K | $297.0K | — | — | — | — | — | — |
| Total assets | $166.1M | $125.4M | $116.5M | $84.8M | $55.7M | $94.8M | $98.6M | $124.9M | $39.5M | $38.1M |
| Accounts payable | $124.0K | $108.0K | $355.0K | $122.0K | $6.4M | $5.9M | $4.3M | $1.2M | $747.0K | $837.0K |
| Total current liabilities | $18.3M | $19.5M | $20.0M | $12.2M | $14.2M | $17.8M | $28.9M | $4.8M | $8.7M | $22.0M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $12.5M | $14.6M | $18.8M | $30.2M | $5.0M | $8.7M | $22.0M |
| Retained earnings | -$68.4M | -$73.5M | -$85.5M | $7.4M | -$402.7M | -$314.8M | -$258.5M | -$203.3M | -$173.5M | -$148.0M |
| Total equity | $106.0M | $63.3M | $13.9M | $72.2M | $59.5M | $76.1M | $68.3M | $119.9M | $30.8M | $16.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M | -$55.0M | -$43.6M | -$28.6M | -$19.9M | -$18.5M |
| Depreciation and amortisation | $2.5M | $1.5M | $1.1M | $1.1M | $290.0K | $138.0K | $146.0K | $149.0K | $173.0K | $389.0K |
| Stock-based compensation | $7.2M | $831.0K | $7.3M | $13.4M | $3.4M | $3.6M | $3.2M | $2.6M | $863.0K | $635.0K |
| Capital expenditure | $1.2M | $2.3M | $8.5M | $5.0M | $839.0K | — | $64.0K | $376.0K | $23.0K | $468.0K |
| Investing cash flow | -$474.0K | -$19.9M | -$19.8M | -$13.8M | $48.2M | $9.7M | $27.4M | -$71.3M | -$11.2M | -$1.3M |
| Financing cash flow | $24.4M | $2.1M | $2.5M | -$45.0M | $49.6M | $60.4M | $327.0K | $111.3M | $21.1M | $948.0K |
| Dividends paid | — | — | — | $45.0M | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-106251.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.0M | $6.0K | — | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | $116.6M |
| Gross profit | — | — | — | — | — | — | $97.5M | $108.8M | $101.9M | $111.2M |
| Net income | -$16.9M | -$21.6M | -$30.1M | -$55.2M | -$56.2M | -$87.9M | $4.3M | -$85.5M | $17.9M | $9.9M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |